MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$33,606K
Free Cash flow
-$39,095K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from long term debt, ne...
    • Acquisition of business, net of ...
    • Proceeds from maturities of mark...
    • Others
Negative Cash Flow Breakdown
    • Proceeds from offerings, net of ...
    • Other assets and liabilities
    • Purchases of property and equipm...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-17,740
-63,316
-17,666
-7,635
Depreciation and amortization expense
6,714
6,809
6,881
6,474
Stock-based compensation expense
6,342
8,996
9,780
10,586
Change in fair value of financial liabilities
-220
-2,540
-1,116
3,401
Deferred tax expense
-518
449
-
246
Provision for excess and obsolete inventory
-
-
-17
29
Legal reserves
-
-
-4,750
-810
Change in third party payor reserves
2,044
-1,022
6,297
-3,732
Loss on extinguishment of debt
0
-6,565
-
-
Impairment loss
0
31,287
0
-
Other
1,123
1,034
781
995
Accounts receivable
6,682
2,558
13,432
12,910
Inventory
5,662
-1,689
3,364
-1,332
Accounts payable and accrued expenses
602
-13,168
6,915
-2,014
Other assets and liabilities
10,896
9,125
-10,143
-10,721
Net cash (used in) provided by operating activities
-28,981
-32,408
-3,090
15,767
Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Series Of Individually Immaterial Business Acquisitions
-
-
32,856
-
Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Gene Dx
-
-
0
-
Acquisition of business, net of cash acquired
-33,195
-
-
0
Purchases of marketable securities
8,888
20,177
19,141
5,765
Proceeds from sales of marketable securities
1,397
875
2,062
0
Proceeds from maturities of marketable securities
11,975
8,500
10,015
7,250
Purchases of property and equipment and development of internal-use software
10,114
6,453
4,347
6,172
Proceeds from sales of assets
-
-
0
-
Development of internal-use software assets
-
-
0
-
Net cash used in investing activities
-5,630
-17,255
-11,072
-4,687
Proceeds from long term debt, net of issuance costs
96,699
-
0
-
Proceeds from offerings, net of issuance costs
-96,998
96,998
21,136
11,802
Proceeds from issuance of common stock from subscription agreements
0
476
-
-
Proceeds from issuance of common stock pursuant to employee stock purchase plan
1,793
-
1,699
0
Exercise of stock options
0
58
1,040
182
Repayment and principal payments for long-term debt-Perceptive Term Loan Facility
0
54,000
-
-
Long-term debt principal payments
-
-
305
304
Repayment and principal payments for long-term debt-DECDLoan Agreement
0
4,447
-
-
Finance lease principal payments
489
495
377
912
Net cash provided by financing activities
1,005
38,590
23,193
10,768
Net decrease in cash, cash equivalents and restricted cash
-33,606
-11,073
9,031
21,848
Cash, cash equivalents and restricted cash, at beginning of period
94,916
105,989
96,958
86,202
Cash, cash equivalents and restricted cash, at end of period
61,310
94,916
105,989
96,958
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from long termdebt, net of issuance...$96,699K Proceeds from issuance ofcommon stock pursuant...$1,793K (42.08%↑ Y/Y)Net cash provided byfinancing activities$1,005K (-92.85%↓ Y/Y)Canceled cashflow$97,487K Net decrease incash, cash...-$33,606K (-202.98%↓ Y/Y)Canceled cashflow$1,005K Depreciation andamortization expense$6,714K (-43.43%↓ Y/Y)Stock-based compensationexpense$6,342K (-46.24%↓ Y/Y)Other$1,123K (-19.03%↓ Y/Y)Accounts payable andaccrued expenses$602K (-91.64%↓ Y/Y)Acquisition of business, netof cash acquired-$33,195K (-200.00%↓ Y/Y)Proceeds from maturitiesof marketable...$11,975K (-55.16%↓ Y/Y)Proceeds from sales ofmarketable securities$1,397K Proceeds from offerings,net of issuance...-$96,998K (-804.62%↓ Y/Y)Finance lease principalpayments$489K (-57.92%↓ Y/Y)Net cash (used in)provided by operating...-$28,981K (-240.67%↓ Y/Y)Net cash used ininvesting activities-$5,630K (87.70%↑ Y/Y)Canceled cashflow$14,781K Canceled cashflow$46,567K Net (loss) income-$17,740K (-514.49%↓ Y/Y)Other assets andliabilities$10,896K (22.51%↑ Y/Y)Accounts receivable$6,682K (-32.43%↓ Y/Y)something is missing-$33,195K Inventory$5,662K (303.28%↑ Y/Y)Change in third partypayor reserves$2,044K (140.77%↑ Y/Y)Deferred tax expense-$518K (-356.44%↓ Y/Y)Change in fair value offinancial liabilities-$220K (79.65%↑ Y/Y)Purchases of property andequipment and development...$10,114K (19.02%↑ Y/Y)Purchases of marketablesecurities$8,888K (-71.11%↓ Y/Y)

GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS)